Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
Stock data | 2023 | Change |
---|---|---|
Shares Outstanding | 5.90M | 0.08% |
Employees | 57.00 | N/A |
Shareholder Equity | 1.77B | 19.22% |
Earnings | 2023 | Change |
---|---|---|
EPS | 48.39 | N/A |